Cost-Utility Analysis of TAVI Versus Surgery in Low-Risk Patients with Severe Aortic Stenosis in the UK
Transcatheter aortic valve implantation with SAPIEN 3 has a 63-90% probability of being cost effective compared with SAVR for low-surgical-risk patients with sSAS. These findings may inform policy decision making in the management of this patient group.
Authors
- Philip A. MacCarthy (ORCID: https://orcid.org/0000-0002-5963-0109)
- Tom Bromilow
- Nick Curzen (ORCID: https://orcid.org/0000-0001-9651-7829)
- Clinton Lloyd (ORCID: https://orcid.org/0009-0006-3858-0444)
- Pascal Candolfi (ORCID: https://orcid.org/0000-0001-6728-451X)
- Daniel J. Blackman (ORCID: https://orcid.org/0000-0001-9039-6130)
- Muhammad Aetesam‐ur‐Rahman (ORCID: https://orcid.org/0000-0003-4010-5627)
- Valentina Sellitto
Institutions
- Leeds Teaching Hospitals NHS Trust (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Leeds and York Partnership NHS Foundation Trust (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- King's College Hospital (GB)
- University Hospitals Plymouth NHS Trust (GB)
- University of Southampton (GB)
- University of York (GB)
- Edwards Lifesciences (Switzerland) (CH)
Publication Details
- Journal
- Applied Health Economics and Health Policy
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1007/s40258-025-01012-4
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Edwards Lifesciences
- University Hospital Southampton NHS Foundation Trust
- University Hospitals Plymouth NHS Trust
- National Institute for Health and Care Research
- King's College London
- University of Oxford
- Oxford University Hospitals NHS Foundation Trust
- NIHR Oxford Biomedical Research Centre